The Tetrad BMI, Leptin, Leptin/Adiponectin (L/A) Ratio and CA-15-3 is a Reliable Biomarker of Breast Cancer (leptin)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Objective:
Evaluate body mass index (BMI), leptin, Leptin/adiponectin (L/A) ratio and cancer antigen (CA) 15-3 together as reliable biomarkers for breast cancer.
Patients:
Consecutive patients aged between 40 - 60 years, with breast disease and informed consent.
Interventions:
Patients' Anthropometric and laboratorial characteristics classified by BMI in the group of cancer and patients with benign breast disease as well as biochemical tests of leptin, adiponectin,CA 15-3, hemoglobin, glucose low-density lipoprotein cholesterol (LDLC), high-density lipoprotein cholesterol (HDLC) levels were obtained as well as a blood sample to analyze CA 15-3 levels with a electrochemiluminescence immunoassay.
Hypothesis:
Using together leptin, L/A ratio, CA 15-3 and BMI could offer a reliable approach to detect high risk women to develop breast cancer.
| Condition |
|---|
|
Female Breast Carcinoma |
| Study Type: | Observational |
| Study Design: | Observational Model: Case Control Time Perspective: Prospective |
| Official Title: | Phase 1. Collect Samples of Breast Biopsy Patients Treated at the Hospital Radiology Service Maternal Perinatal Monica Pretelini |
serum
| Enrollment: | 88 |
| Study Start Date: | January 2011 |
| Study Completion Date: | July 2012 |
| Primary Completion Date: | October 2011 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
breast cancer patients (cases)
36 subjects
|
|
controls
36 subjects
|
Detailed Description:
Serum levels of leptin, adiponectin and CA 15-3, as well as anthropometric and biochemical parameters were analyzed in 88 female patients attending mammography study. Predictive values of BMI, leptin, L/A ratio and CA 15-3 were determined with 95% confidence interval (CI).
Eligibility| Ages Eligible for Study: | 40 Years to 60 Years |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
Cross-sectional prospective study conducted at the Maternal-Perinatal Hospital "Mónica Pretelini" (HMPMP), State of Mexico Health Institute (ISEM), Toluca, Mexico, from January to October 2011.
Inclusion Criteria:
- Female patients attending mammography, average age of the fourth and fifth decades.
Exclusion Criteria:
- Patients with hormonal therapy.
Contacts and Locations| Principal Investigator: | Jonnathan Guadalupe Santillán Benítez, MSc | Autonomus University Of the State Of México |
| Study Director: | Leobardo Manuel Gómez Oliván, PhD | Universidad Autonoma del Estado de Mexico |
| Study Chair: | Hugo Mendieta Zeron, PhD | Autonomous University of the State of Mexico |
More Information
No publications provided by Materno-Perinatal Hospital of the State of Mexico
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Hugo Mendieta Zeron, PhD, Materno-Perinatal Hospital of the State of Mexico |
| ClinicalTrials.gov Identifier: | NCT01643148 History of Changes |
| Other Study ID Numbers: | DCQ |
| Study First Received: | July 16, 2012 |
| Last Updated: | July 17, 2012 |
| Health Authority: | Mexico: Secretaria de Salud |
Keywords provided by Materno-Perinatal Hospital of the State of Mexico:
|
biomarker BMI breast cancer CA-15-3 leptin |
Additional relevant MeSH terms:
|
Breast Neoplasms Carcinoma Neoplasms by Site Neoplasms |
Breast Diseases Skin Diseases Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type |
ClinicalTrials.gov processed this record on May 22, 2013